Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Atezolizumab and Targeted Therapy in Thyroid Cancer
TOPLINE: Atezolizumab combined with targeted therapy improved median overall survival to 19 months in patients with anaplastic thyroid carcinoma (ATC). The longest survival was observed in the BRAF V600E cohort, with a median overall survival of 43 months. METHODOLOGY: The…
English